Table 4.

Dose-response in primary and secondary outcomes.

Variables		Rawa		Adjustedb		Imputedc
		B	P	B	P	B	P
BDI-II
	CACE analysisd	-6.93 (-12.52 to -1.33)	.016	-7.24 (-12.33 to -2.15)	.006	-8.07 (-9.42 to -6.72)	<.001
	Effect per session	-0.65 (-1.18 to -0.13)	.015	-0.68 (-1.16 to -0.20)	.006	-0.73 (-0.85 to -0.61)	<.001
Mental SF-12
	CACE analysisd	9.42 (3.08 to 15.75)	.004	10.27 (4.01 to 16.52)	.001	10.59 (9.05 to 12.12)	<.001
	Effect per session	0.89 (0.29 to 1.48)	.004	0.97 (0.38 to 1.56)	.001	0.95 (0.82 to 1.09)	<.001
Physical SF-12
	CACE analysisd	0.01 (-5.71 to 5.74)	.996	0.65 (-3.85 to 5.16)	.776	0.29 (-1.07 to 1.64)	.676
	Effect per session	<1.01 (-0.54 to 0.54)	.996	0.06 (-0.36 to 0.49)	.775	0.03 (-0.10 to 0.15)	.676
EuroQol VAS
	CACE analysisd	11.44 (0.76 to 22.12)	.036	12.18 (2.22 to 22.13)	.017	13.12 (10.58 to 15.66)	<.001
	Effect per session	1.08 (0.08 to 2.07)	.034	1.15 (0.22 to 2.07)	.016	1.18(0.96 to 1.41)	<.001

^aUsing raw models.

^bAdjusting baseline, sex and age.

^cUsing imputed data.

^dCompliance as attendance at >6 sessions. B: regression coefficients. Controls were considered as receiving 0 sessions.